<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3668">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834102</url>
  </required_header>
  <id_info>
    <org_study_id>2021/0123</org_study_id>
    <nct_id>NCT04834102</nct_id>
  </id_info>
  <brief_title>COVID-19 Induced Telogen Effluvium</brief_title>
  <official_title>COVID-19 Induced Telogen Effluvium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study inquires about the development of Telogen effluvium following the SARS-CoV-2&#xD;
      infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telogen effluvium (TE) is one of the most common causes of non-scarring alopecia. During the&#xD;
      COVİD-19 pandemic, there is an increased number of Telogen effluvium patients.This study&#xD;
      inquires about the development of Telogen effluvium following the SARS-CoV-2 infection and&#xD;
      correlation between the severity of covid-19 and TE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">April 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hair shedding</measure>
    <time_frame>3 months</time_frame>
    <description>Physical examination of hair and scalp, trichoscopy, hair pull test</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>Telogen Effluvium</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Alopecia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Tests</intervention_name>
    <description>Evaluation of blood ferritin, hemoglobine, serum iron and serum iron binding capacity</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults that are diagnosed with COVID-19 in the past year.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sars-CoV-2 infection in the past year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other common causes of Telogen effluvium ( such as anemia, iron deficiency, thyroid&#xD;
             dysfunction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan AKSOY, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Medeniyet University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umut Mert YILDIRIM, Dr.</last_name>
    <phone>+905423383842</phone>
    <email>umutmertyildirim@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasan AKSOY, Dr.</last_name>
    <phone>+905053005460</phone>
    <email>haxoil@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul Medeniyet University</name>
      <address>
        <city>Istanbul</city>
        <state>Kadıköy</state>
        <zip>34720</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umut Mert YILDIRIM, Dr.</last_name>
      <phone>+905423383842</phone>
      <email>umutmertyildirim@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hasan Aksoy, Specialist Dr.</last_name>
      <phone>+905053005460</phone>
      <email>haxoil@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hasan AKSOY, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Umut Mert YILDIRIM, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pınar ERGEN, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehmet Salih GUREL, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27;12(5):e8320. doi: 10.7759/cureus.8320. Review.</citation>
    <PMID>32607303</PMID>
  </results_reference>
  <results_reference>
    <citation>Mieczkowska K, Deutsch A, Borok J, Guzman AK, Fruchter R, Patel P, Wind O, McLellan BN, Mann RE, Halverstam CP. Telogen effluvium: a sequela of COVID-19. Int J Dermatol. 2021 Jan;60(1):122-124. doi: 10.1111/ijd.15313. Epub 2020 Nov 23.</citation>
    <PMID>33226117</PMID>
  </results_reference>
  <results_reference>
    <citation>Rizzetto G, Diotallevi F, Campanati A, Radi G, Bianchelli T, Molinelli E, Mazzanti S, Offidani A. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021 Jan;34(1):e14547. doi: 10.1111/dth.14547. Epub 2020 Nov 23.</citation>
    <PMID>33190397</PMID>
  </results_reference>
  <results_reference>
    <citation>Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID-19. J Am Acad Dermatol. 2021 Mar;84(3):773-775. doi: 10.1016/j.jaad.2020.11.032. Epub 2020 Dec 10.</citation>
    <PMID>33310111</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Hasan Aksoy</investigator_full_name>
    <investigator_title>Specialist Dr.</investigator_title>
  </responsible_party>
  <keyword>Telogen Effluvium</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Alopecia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

